Dr. Jan G.J. van de Winkel, Ph D., is CEO & Executive Director of Merus N.V. from December 11, 2025. Dr. van de Winkel is a co-founder of Genmab and served as President, Research & Development and Chief Sc...

리더십 팀

이름	직위	재임 기간	보수	지분
Gregory Perry	Chief Financial Officer	2.5yrs	US$3.26m	0% $ 0
Peter Silverman	EVP, Company Secretary	7.8yrs	US$3.40m	0% $ 0
Fabian Zohren	Chief Medical Officer	1.4yrs	US$7.20m	0% $ 0
Jan van de Winkel	CEO & Executive Director	no data	데이터 없음	데이터 없음
Hennie Hoogenboom	Co-Founder and Scientific Advisor	no data	데이터 없음	데이터 없음
Harry Shuman	Chief Accounting Officer	no data	데이터 없음	0% $ 0
Cornelis de Kruif	CTO & Executive VP	12.9yrs	US$609.22k	데이터 없음
Cecilia Anna Geuijen	Chief Scientific Officer & Senior VP	4.6yrs	데이터 없음	데이터 없음
Sherri Spear	Senior Vice President of Investor Relations & Strategic Communications	no data	데이터 없음	데이터 없음
Kathleen Farren	Director of IR & Corporate Communications Officer	no data	데이터 없음	데이터 없음
Audrey Bergan	Chief People Officer	1.1yrs	데이터 없음	데이터 없음
Shannon Campbell	Executive VP & Chief Commercial Officer	3.8yrs	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

59yo

평균 나이

경험이 풍부한 관리: MRUS의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.2 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/12/31 04:37
종가	2025/12/29 00:00
수익	2025/09/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Merus N.V.는 29명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Matthew Venezia	Alliance Global Partners
Etzer Darout	Barclays
Evan Seigerman	BMO Capital Markets Equity Research

This company has been acquired

Merus 경영진

경영진 기준 점검 1/4

핵심 정보

최근 경영진 업데이트

Merus N.V., Annual General Meeting, May 21, 2025

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

EVP, Company Secretary notifies of intention to sell stock

Merus Appoints Greg Perry as Chief Financial Officer

Recent updates

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Composite Index

Merus to Delist All Common Shares from Nasdaq

Merus N.V.(NasdaqGM:MRUS) dropped from NASDAQ Biotechnology Index

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab Buys Merus For $8bn: A Good Deal If Potential Is Converted Into Revenue

Genmab Reportedly in Advanced Talks to Buy Merus

Merus N.V. has completed a Follow-on Equity Offering in the amount of $300.000006 million.

Merus, N.V. Provides Updates on Clinical Development

Merus N.V. Announces Interim Data Demonstrates Robust Efficacy and Durability in 1L Pembrolizumab

Merus N.V., Annual General Meeting, May 21, 2025

Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025

Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Here's Why We're Not Too Worried About Merus' (NASDAQ:MRUS) Cash Burn Situation

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus Stock: Rally Seems Overdone

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus Appoints Greg Perry as Chief Financial Officer

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Consensus revenue estimates increase by 15%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Executive VP exercised options and sold US$947k worth of stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind